Multiple myeloma (MM) is due to the proliferation in the bone marrow of malignant plasmacells and accounts
for about 10% of all hematological tumors. MM is the natural evolution of a monoclonal gammopathy of uncertain significance.
Although the introduction of novel biological agents in the clinical practice has changed the natural history of
the disease, MM remains incurable. MicroRNAs (miRNAs) are short non-coding RNAs that control cell functions through
mRNA targeting. In the cancer setting, miRNAs have shown prognostic and predictive potentials. Several preclinical findings
demonstrate their broad anticancer activities in various types of cancer, including MM. In this article, we provide an
overview of the biology of miRNAs focusing on the role of miRNA deregulation in MM pathogenesis. These findings
represent the basis to discuss the potential role of miRNAs as therapeutic agents against MM.
Keywords: Bone disease, microRNA, multiple myeloma, non-coding RNA, target therapy.
Rights & PermissionsPrintExport